Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy,
 tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin
 for treatment of uncomplicated urinary tract infection (uUTI) in adult women
Inclusion Criteria:

 1. Female patients ≥18 years of age with 24-96 hours of urinary symptoms attributable to
 a urinary tract infection (UTI)

 2. Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency,
 pain or burning micturition, suprapubic pain

 3. A mid-stream urine specimen with:

 1. a dipstick analysis positive for nitrite AND

 2. evidence of pyuria as defined by either:

 i. a dipstick analysis positive for leukocyte esterase ii. at least 10 white blood
 cells per cubic millimeter on microscopic analysis of unspun urine iii. White blood
 cell count ≥10 cells/high-powered field in the sediment of a spun urine

 4. Has given written informed consent to participate in the study.

 Exclusion Criteria:

 1. Presence of signs and symptoms suggestive of acute pyelonephritis: fever (temperature
 > 38°Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or
 vomiting

 2. Receipt of antibacterial drug therapy potentially effective as treatment of uUTI
 within the prior 7 days

 3. Concurrent use of non-study treatments that would have a potential effect on outcome
 evaluations in patients with uUTI

 4. Patients with ileal loops or urinary stoma

 5. Patients with an indwelling urinary catheter in the previous 30 days

 6. Patients with paraplegia

 7. Patients who are likely to receive ongoing antibacterial drug prophylaxis after
 treatment of uUTI (e.g., patients with vesico-ureteral reflux)

 8. Any history of trauma to the pelvis or urinary tract

 9. Patient's urine culture, if available at study entry, identify more than 2
 microorganisms regardless of colony count or patient has a confirmed fungal UTI

 10. Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant

 11. Known history of creatinine clearance <50 mL/min

 12. Patients known to have liver disease

 13. Patients who are pregnant, or females of child-bearing age unable to take adequate
 contraceptive precautions

 14. Patients with uncontrolled diabetes mellitus

 15. Patients with history of blood dyscrasias

 16. Patients with history of uric acid kidney stones

 17. Patients with acute gouty attack

 18. Patients on chronic methotrexate therapy

 19. Patient known to be immunocompromised

 20. Patients with a known history of myasthenia gravis

 21. Patients who require concomitant administration of tizanidine or valproic acid

 22. Patients with a history of allergy or hypersensitivity to carbapenems, beta-lactams,
 quinolones or probenecid

 23. Patient is considered unlikely to survive the 4-week study period or has a rapidly
 progressive or terminal illness including septic shock which is associated with a high
 risk of mortality

 24. History of seizures

 25. Use of any other investigational drug in the 30 days prior to the study